Literature DB >> 16371011

The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease.

Daniela C Glatz1, Dan Rujescu, Yesheng Tang, Frank J Berendt, Annette M Hartmann, Frank Faltraco, Carlyn Rosenberg, Christine Hulette, Kurt Jellinger, Harald Hampel, Peter Riederer, Hans-J Möller, Athena Andreadis, Kerstin Henkel, Stefan Stamm.   

Abstract

Pathological inclusions containing fibrillar aggregates of hyperphosphorylated tau protein are a characteristic feature in tauopathies, which include Alzheimer's disease (AD). Tau is a microtubule-associated protein whose transcript undergoes alternative splicing in the brain. Exon 10 encodes one of four microtubule-binding repeats. Exon 10 inclusion gives rise to tau protein isoforms containing four microtubule-binding repeats (4R) whereas exclusion leads to isoforms containing only three repeats (3R). The ratio between 3R and 4R isoforms is tightly controlled via alternative splicing in the human adult nervous system and distortion of this balance results in neurodegeneration. Previous studies showed that several splicing regulators, among them hTRA2-beta1 and CLK2, regulate exon 10 alternative splicing. Like most splicing factors, htra2-beta and clk2 pre-mRNAs are regulated by alternative splicing. Here, we investigated whether human postmortem brain tissue of AD patients reveal differences in alternative splicing patterns of the tau, htra2-beta, presenilin 2 and clk2 genes when compared with age-matched controls. We found that the splicing patterns of all four genes are altered in affected brain areas of sporadic AD patients. In these affected areas, the amount of mRNAs of tau isoforms including exon 10, the htra2-beta1 isoform and an inactive form of clk2 are significantly increased. These findings suggest that a misregulation of alternative splicing seems to contribute to sporadic AD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16371011     DOI: 10.1111/j.1471-4159.2005.03552.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  65 in total

1.  SR protein 9G8 modulates splicing of tau exon 10 via its proximal downstream intron, a clustering region for frontotemporal dementia mutations.

Authors:  Lei Gao; Junning Wang; Yingzi Wang; Athena Andreadis
Journal:  Mol Cell Neurosci       Date:  2006-11-29       Impact factor: 4.314

2.  Therapeutic potential and mechanism of kinetin as a treatment for the human splicing disease familial dysautonomia.

Authors:  Matthew M Hims; El Chérif Ibrahim; Maire Leyne; James Mull; Lijuan Liu; Conxi Lazaro; Ranjit S Shetty; Sandra Gill; James F Gusella; Robin Reed; Susan A Slaugenhaupt
Journal:  J Mol Med (Berl)       Date:  2007-01-06       Impact factor: 4.599

3.  Differential incorporation of tau isoforms in Alzheimer's disease.

Authors:  Marisol Espinoza; Rohan de Silva; Dennis W Dickson; Peter Davies
Journal:  J Alzheimers Dis       Date:  2008-05       Impact factor: 4.472

4.  Tau as a biomarker of neurodegenerative diseases.

Authors:  Susanna Schraen-Maschke; Nicolas Sergeant; Claire-Marie Dhaenens; Stéphanie Bombois; Vincent Deramecourt; Marie-Laure Caillet-Boudin; Florence Pasquier; Claude-Alain Maurage; Bernard Sablonnière; Eugeen Vanmechelen; Luc Buée
Journal:  Biomark Med       Date:  2008-08       Impact factor: 2.851

5.  Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer.

Authors:  Christine M Misquitta-Ali; Edith Cheng; Dave O'Hanlon; Ni Liu; C Jane McGlade; Ming Sound Tsao; Benjamin J Blencowe
Journal:  Mol Cell Biol       Date:  2010-11-01       Impact factor: 4.272

6.  Expression of the splicing factor gene SFRS10 is reduced in human obesity and contributes to enhanced lipogenesis.

Authors:  Jussi Pihlajamäki; Carles Lerin; Paula Itkonen; Tanner Boes; Thomas Floss; Joshua Schroeder; Farrell Dearie; Sarah Crunkhorn; Furkan Burak; Josep C Jimenez-Chillaron; Tiina Kuulasmaa; Pekka Miettinen; Peter J Park; Imad Nasser; Zhenwen Zhao; Zhaiyi Zhang; Yan Xu; Wolfgang Wurst; Hongmei Ren; Andrew J Morris; Stefan Stamm; Allison B Goldfine; Markku Laakso; Mary Elizabeth Patti
Journal:  Cell Metab       Date:  2011-08-03       Impact factor: 27.287

7.  PSF suppresses tau exon 10 inclusion by interacting with a stem-loop structure downstream of exon 10.

Authors:  Payal Ray; Amar Kar; Kazuo Fushimi; Necat Havlioglu; Xiaoping Chen; Jane Y Wu
Journal:  J Mol Neurosci       Date:  2011-09-01       Impact factor: 3.444

8.  Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I: A MOLECULAR MECHANISM LINKED TO TAU PATHOLOGY IN ALZHEIMER DISEASE.

Authors:  Nana Jin; Xiaomin Yin; Jianlan Gu; Xinhua Zhang; Jianhua Shi; Wei Qian; Yuhua Ji; Maohong Cao; Xiaosong Gu; Fei Ding; Khalid Iqbal; Cheng-Xin Gong; Fei Liu
Journal:  J Biol Chem       Date:  2015-04-27       Impact factor: 5.157

Review 9.  Alternative splicing and disease.

Authors:  Jamal Tazi; Nadia Bakkour; Stefan Stamm
Journal:  Biochim Biophys Acta       Date:  2008-10-17

10.  Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).

Authors:  Bryan T Mott; Cordelle Tanega; Min Shen; David J Maloney; Paul Shinn; William Leister; Juan J Marugan; James Inglese; Christopher P Austin; Tom Misteli; Douglas S Auld; Craig J Thomas
Journal:  Bioorg Med Chem Lett       Date:  2009-10-03       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.